SQSTM1 and systemic lupus erythematosus: Compounds which elevate SQSTM1/p62 levels, like rapamycin [132] and trehalose [133], are being therefore studied in several phase II and III trials in connection with diabetes mellitus, systemic lupus erythematosus, and autosomal dominant polycystic kidney disease.